What is the Value of Real World Evidence in Oncology in HTA Appraisals?
ICON Pricing and Market Access experts conducted an analysis to assess the value of RWE in recent HTA appraisals.
Limiting Potential Carcinogenic Risk in Drug Development with Reliable Predictions
ICON's Mgr, Nonclinical Safety Assessment, Drug Development Consulting discusses the challenges & opportunities of in silico analysis in toxicology.
An Introduction to Applications of Adaptive Design
The adoption of an adaptive design strategy across the product development process brings a number of important benefits
Lean and Mean Biosimilar Trial Design
Biosimilar clinical trials shows that strategic planning and a few simple tactics can increase return on investment and expedite time to market for biosimilars
Why you should consider using a Learning Management System
Centralising and tracking training requirements for your trials through a learning management system to make it easier for site and study staff.
Key Considerations for Achieving Digital Trial Success
Digital disruption are emerging to enable pharma and med device companies generate new datasets.
Improving Responses to Medical Device Vulnerabilities
Discover how manufacturers can improve responses to cybersecurity threats.
EMA ISO IDMP - The path forward
The EMA is implementing the standards developed by the ISO for the IDMP.
Simplifying the process of documenting Analysis Results Metadata (ARM)
Automating the process for Define –XML with ARM
Smart Bioanalytical Strategies in Immuno-Oncology Trials
Discover the latest biomarker-based methods and how they can be leveraged to add value to oncology trials.
CDISC Legacy Data Conversion
ICON’s Data Management team provides advice and guidance on legacy conversion process and what you need to implement to remain compliant.
Precision Medicine Opportunities for Device Developers
Medical device developers are emerging into the precision medicine market in a variety of therapeutic areas, including neurology, cardiology and infectious diseases.
Five Key Considerations for Writing First-in-Human Protocols Under EMA Guidelines
As pharmaceuticals move from animal to first-in-human (FIH) clinical trials, establishing appropriate strategies to minimise risk in early phase clinical trials is necessary.
What Motivates Patients to Participate in Multiple Clinical Trials?
Successful clinical trial recruitment requires a thorough understanding of the target patient profile, and a key factor within this profile is patient motivation.
FDA Acceptance of Clinical Data Collected Outside the U.S.
The US Food & Drug Administration (FDA) amended requirements for the acceptance of clinical data cllected outside the US to support medical device submissions.
Harnessing Blockchain Technology and Digital Disruption
The opportunity for blockchain in healthcare and clinical trials.
The Future of Automation and Digital Transformation in Late Phase Research
Late phase studies are ripe for digitalisation, although not always in the same ways as Phase II and III programs.
Biostatistics: Using Restricted Mean Survival Time (RMST) in Oncology Trials to Improve Outcomes
Learn how to use biostatistics using RMST in Oncological trials to improve clinical outcomes
NASH Clearing Clinical Trial Hurdles in Race to $35 billion Market
NASH ranks among the world’s great emerging health threats
Controlling Logistics Costs Can Significantly Reduce Trial Lab Expenses
ICON has developed a lab logistics program to reduce costs